ArriVent BioPharma (AVBP) said late Tuesday it has entered into an exclusive licensing agreement with Lepu Biopharma to develop and commercialize gastrointestinal cancer drug MRG007 outside of Greater China.
Under the terms of the deal, Lepu Biopharma will get an upfront payment and near-term milestone payments totaling $47 million in cash and will be eligible to receive up to $1.16 billion in development, regulatory and sales milestones and tiered royalties on net sales outside of Greater China.
The payments and research and development costs will not change ArriVent's expected cash runway into 2026, the company said.
MRG007 has shown antitumor activity in preclinical models, the company said, adding that an investigational new drug submission is planned for H1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。